Company intelligence / Profile preview

RAN-Citalopram

Mumbai, Maharashtra, India

Ownership: Private
Employees: ~41000
Development stage: Other

Overview

Sun Pharmaceutical Industries is a leading global specialty generic pharmaceutical company and the largest pharmaceutical firm in India. The company provides high-quality, affordable medicines trusted by healthcare professionals and patients in over 100 countries. Its extensive portfolio includes the RAN- line of generic products, such as RAN-Citalopram, which originated from Ranbaxy Laboratories before its acquisition by Sun Pharma in 2015. Sun Pharma's business encompasses generics, branded generics, specialty products, and active pharmaceutical ingredients (APIs) across diverse therapeutic areas like psychiatry, oncology, and dermatology.

Therapeutic areas: Psychiatry
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on RAN-Citalopram.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RAN-Citalopram.

Explore the full profile